Voting Questions for the Committee

1. For the composition of the trivalent 2017-2018 influenza virus vaccine in the U.S., does the committee recommend:
   A. Inclusion of an A/Michigan/45/2015 (H1N1)pdm09-like virus
   B. Inclusion of an A/Hong Kong/4801/2014 (H3N2)-like virus
   C. Inclusion of a B/Brisbane/60/2008-like virus (B/Victoria lineage)

2. For quadrivalent 2017-2018 influenza vaccines in the U.S., does the committee recommend:
   A. Inclusion of a B/Phuket/3073/2013-like virus (B/Yamagata lineage) as the 2nd influenza B strain in the vaccine